Clinically benign multiple sclerosis despite large T2 lesion load: Can we explain this paradox?
暂无分享,去创建一个
S Ropele | F Fazekas | C. Enzinger | S. Ropele | F. Fazekas | S Strasser-Fuchs | C Enzinger | M Wallner | S. Strasser‐Fuchs | M. Wallner | C. Enzinger | Franz Fazekas
[1] D.L. Plummer,et al. DispImage: Un mezzo di analisi e presentazione per iconografia medica , 1992 .
[2] D Origgi,et al. Benign versus secondary-progressive multiple sclerosis: the potential role of proton MR spectroscopy in defining the nature of disability. , 1998, AJNR. American journal of neuroradiology.
[3] M. Filippi,et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes , 2005, The Lancet Neurology.
[4] R. Bakshi,et al. Measurement of Brain and Spinal Cord Atrophy by Magnetic Resonance Imaging as a Tool to Monitor Multiple Sclerosis , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.
[5] M. Filippi,et al. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS) , 2005, Multiple sclerosis.
[6] M. Battaglini,et al. Brain damage as detected by magnetization transfer imaging is less pronounced in benign than in early relapsing multiple sclerosis. , 2006, Brain : a journal of neurology.
[7] T Locatelli,et al. Brain magnetic resonance imaging and multimodal evoked potentials in benign and secondary progressive multiple sclerosis. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[8] Sridar Narayanan,et al. Axonal Damage in Multiple Sclerosis Patients with High versus Low Expanded Disability Status Scale Score , 2004, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[9] Frederik Barkhof,et al. Grey matter pathology in multiple sclerosis , 2008, The Lancet Neurology.
[10] P M Matthews,et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. , 2001, Archives of neurology.
[11] A. Thompson,et al. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis , 2006, Journal of Neurology, Neurosurgery & Psychiatry.
[12] Massimo Filippi,et al. The use of quantitative magnetic-resonance-based techniques to monitor the evolution of multiple sclerosis , 2003, The Lancet Neurology.
[13] S. Reingold,et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. , 1998, Brain : a journal of neurology.
[14] C. Mainero,et al. Correlates of MS disability assessed in vivo using aggregates of MR quantities , 2001, Neurology.
[15] F. Fazekas,et al. Discrimination of white matter lesions and multiple sclerosis plaques by short echo quantitative 1H—magnetic resonance spectroscopy , 2005, Journal of Neurology.
[16] M Rovaris,et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. , 2003, Brain : a journal of neurology.
[17] P. Gallo,et al. The HLA-DR13 haplotype is associated with “benign” multiple sclerosis in northeast Italy , 2001, Neurology.
[18] D. Li,et al. Benign versus chronic progressive multiple sclerosis: Magnetic resonance imaging features , 1989, Annals of neurology.
[19] M. Filippi. Magnetization transfer MRI in multiple sclerosis and other central nervous system disorders , 2003, European journal of neurology.
[20] J. Kurtzke. Rating neurologic impairment in multiple sclerosis , 1983, Neurology.
[21] G. Barker,et al. Effect of interferon‐β1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: Results of a European multicenter, randomized, double‐blind, placebo‐controlled trial , 1999 .
[22] Antonio Federico,et al. Diffuse axonal and tissue injury in patients with multiple sclerosis with low cerebral lesion load and no disability. , 2002, Archives of neurology.
[23] D. Arnold,et al. The role of MRS and fMRI in multiple sclerosis. , 2006, Advances in neurology.
[24] V. Haughton,et al. Correlation of magnetic resonance imaging with neuropsychological testing in multiple sclerosis , 1989, Neurology.
[25] F. Barkhof. The clinico‐radiological paradox in multiple sclerosis revisited , 2002, Current opinion in neurology.
[26] C. Enzinger,et al. Lower Levels of N-Acetylaspartate in Multiple Sclerosis Patients With the Apolipoprotein E ϵ4 Allele , 2003 .
[27] A. J. Thompson,et al. Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis , 2003, Journal of Neurology.
[28] Frederik Barkhof,et al. MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS) , 1999, Multiple sclerosis.
[29] J. Geurts,et al. Grey matter pathology in multiple sclerosis , 2006, Acta neurologica Scandinavica. Supplementum.
[30] G. Barker,et al. Magnetisation transfer ratio: a robust measure of myelin content in post-mortem multiple sclerosis brain , 2004 .
[31] G J Barker,et al. Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. , 1999, Annals of neurology.
[32] D. Li,et al. Randomized controlled trial of interferon-beta-1a in secondary progressive MS , 2001, Neurology.
[33] Estimation of magnetization transfer rates from PACE experiments with pulsed RF saturation , 2000, Journal of magnetic resonance imaging : JMRI.
[34] L. Blumhardt,et al. The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three‐dimensional MRI study , 2003, Acta neurologica Scandinavica.
[35] D. Arnold,et al. Magnetic resonance techniques for the in vivo assessment of multiple sclerosis pathology: Consensus report of the white matter study group , 2005, Journal of magnetic resonance imaging : JMRI.
[36] J. De Keyser,et al. Benign course in multiple sclerosis: a review , 2006, Acta neurologica Scandinavica.
[37] G J Barker,et al. Disability in multiple sclerosis is related to normal appearing brain tissue MTR histogram abnormalities , 2003, Multiple sclerosis.
[38] Lublin Fd,et al. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. , 1996 .
[39] S. Provencher. Estimation of metabolite concentrations from localized in vivo proton NMR spectra , 1993, Magnetic resonance in medicine.
[40] P. Matthews,et al. Normalized Accurate Measurement of Longitudinal Brain Change , 2001, Journal of computer assisted tomography.
[41] R Stollberger,et al. T1 maps from shifted spin echoes and stimulated echoes , 2001, Magnetic resonance in medicine.
[42] S Ropele,et al. Quantitative magnetization transfer imaging of pre-lesional white-matter changes in multiple sclerosis , 2002, Multiple sclerosis.
[43] Nick C Fox,et al. Magnetic resonance imaging measures of brain atrophy in multiple sclerosis , 2006, Journal of magnetic resonance imaging : JMRI.
[44] J S Wolinsky,et al. EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis , 2006, European journal of neurology.